Acceleron Pharma Inc. (NASDAQ:XLRN)’s share price fell 3.8% during trading on Wednesday . The company traded as low as $33.24 and last traded at $33.77, with a volume of 82,665 shares. The stock had previously closed at $35.10.

A number of research firms recently commented on XLRN. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Acceleron Pharma in a research report on Sunday, April 17th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Acceleron Pharma in a research report on Sunday, July 10th. Leerink Swann reaffirmed a “buy” rating on shares of Acceleron Pharma in a research report on Sunday, June 12th. Zacks Investment Research raised shares of Acceleron Pharma from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research report on Wednesday, April 27th. Finally, FBR & Co reaffirmed a “buy” rating and set a $63.00 price target on shares of Acceleron Pharma in a research report on Monday, June 13th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Acceleron Pharma has a consensus rating of “Buy” and an average price target of $48.14.

The company has a 50 day moving average of $34.66 and a 200-day moving average of $31.57. The firm’s market cap is $1.23 billion.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.40. The business had revenue of $18.20 million for the quarter, compared to analysts’ expectations of $8.70 million. Acceleron Pharma’s revenue for the quarter was up 311.8% compared to the same quarter last year. During the same period last year, the company earned ($0.45) earnings per share. Analysts predict that Acceleron Pharma Inc. will post ($1.55) earnings per share for the current year.

In other news, CEO John L. Knopf sold 100,000 shares of the stock in a transaction dated Wednesday, July 6th. The shares were sold at an average price of $33.87, for a total value of $3,387,000.00. Following the sale, the chief executive officer now directly owns 147,106 shares of the company’s stock, valued at $4,982,480.22. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO John L. Knopf sold 30,501 shares of the stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $33.26, for a total transaction of $1,014,463.26. Following the completion of the sale, the chief executive officer now directly owns 147,106 shares in the company, valued at $4,892,745.56. The disclosure for this sale can be found here.

Several large investors have recently made changes to their positions in the company. Rhumbline Advisers increased its stake in shares of Acceleron Pharma by 7.7% in the fourth quarter. Rhumbline Advisers now owns 20,643 shares of the biopharmaceutical company’s stock worth $1,007,000 after buying an additional 1,475 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Acceleron Pharma by 272.9% in the fourth quarter. Wells Fargo & Company MN now owns 24,264 shares of the biopharmaceutical company’s stock worth $1,183,000 after buying an additional 17,758 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of Acceleron Pharma by 9.6% in the fourth quarter. ProShare Advisors LLC now owns 29,906 shares of the biopharmaceutical company’s stock worth $1,458,000 after buying an additional 2,619 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Acceleron Pharma by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 40,191 shares of the biopharmaceutical company’s stock worth $1,960,000 after buying an additional 642 shares during the last quarter. Finally, Mutual of America Capital Management LLC increased its stake in shares of Acceleron Pharma by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 44,363 shares of the biopharmaceutical company’s stock worth $2,163,000 after buying an additional 260 shares during the last quarter.

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. Its segment operates through discovery, development and commercialization of protein therapeutics for cancer and rare diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.